{"id":952771,"date":"2026-04-20T07:33:15","date_gmt":"2026-04-20T11:33:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/"},"modified":"2026-04-20T07:33:15","modified_gmt":"2026-04-20T11:33:15","slug":"briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/","title":{"rendered":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4\/6 inhibitor treatments shows quality of life (QOL) largely preserved<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Identification of potential prognostic biomarkers upon further analyses of Phase 2 Bria-IMT\u2122 study data<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Bria-OTS+\u2122 in Preclinical Cancer Models to be presented on Tuesday April 21 from 2:00- 5:00 PM PST; Poster Number: 6701<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, April  20, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17\u201322 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g47owSoNONNXdzNIOAmtsnxhjocLaQLuX5hrgjEaEUUEouO9bGCbxc9ohdEDsN4Uls4UDKyhCmpnbluBuqYRJn6tP5zXRP7Z_cR7F6L2571ctNgaLUFXzAugBOpIfr4X\" rel=\"nofollow\" target=\"_blank\"><strong>NCT06072612<\/strong><\/a>), and two posters highlighting further analyses of Phase 2 data. Abstracts will be published in the online Proceedings of the AACR.<\/p>\n<p align=\"justify\">\u201cStandards of care in cancer are evolving rapidly as innovative immunotherapy approaches emerge with potentially better safety profiles than chemotherapy. Clinical data, including BriaCell\u2019s, highlight that maintaining quality of life is an important treatment goal alongside efficacy and safety,\u201d stated lead author, Saranya Chumsri, MD, Principal Investigator of BriaCell Phase 3 study of Bria-IMT+CPI, and Professor of Oncology, Mayo Clinic.<\/p>\n<p align=\"justify\">\u201cAt BriaCell, we are focused on bringing novel therapeutics to cancer patients with unmet medical needs with the ultimate goal of improving patients\u2019 lives,\u201d noted William V. Williams, MD, BriaCell\u2019s President &amp; CEO. \u201cOur new quality of life data from the Phase 3 Bria-IMT + CPI study in patients with metastatic breast cancer who failed prior therapies show very positive trends, bringing us one step closer to transforming care for these patients.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Session Title:<\/strong>\u00a0Phase II and Phase III Clinical Trials<br \/><strong>Session: <\/strong>4\/20\/2026 2:00-5:00 PM PST<br \/><strong>Location:<\/strong>\u00a0Poster Section 52<br \/><strong>Poster Board Number:<\/strong>\u00a01<br \/><strong>Poster Number:<\/strong>\u00a0CT137 <br \/><strong>Title:<\/strong> QOL Outcomes in Bria-ABC Late-Stage Metastatic Phase 3 Trial<br \/><strong>Summary:<\/strong> Heavily pretreated metastatic breast cancer patients in the pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor maintained overall health status and key functional measures with a favorable safety profile. These findings are encouraging because they suggest meaningful preservation of quality of life for late-stage metastatic breast cancer patients with limited treatment options.<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">QOL largely preserved in a heavily pretreated population with prior antibody-drug conjugate (ADC), check point inhibitor (CPI), and cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor exposure<\/li>\n<li style=\"text-align:left\">European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Survey showed:\u00a0<br \/>1)\u00a0\u00a0\u00a0Global health status stable through early and mid-treatment<br \/>2)\u00a0\u00a0\u00a0Emotional and cognitive functioning maintained; symptom burden stable<\/li>\n<li style=\"text-align:left\">Safety profile and time-to-deterioration analyses support durable tolerability in a late-line setting<\/li>\n<li style=\"text-align:left\">BriaCell clinical data supports feasibility of decentralized treatment approaches, including potential home self-administration strategies<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Session Category:<\/strong>\u00a0Clinical Research<br \/><strong>Session: <\/strong>4\/19\/2026 2:00<strong>&#8211;<\/strong>5:00 PM PST<br \/><strong>Location:<\/strong>\u00a0Poster Section 42<br \/><strong>Poster Board Number:<\/strong>\u00a05<br \/><strong>Poster Number:<\/strong>\u00a01065 <br \/><strong>Title<\/strong>: Mitosis in Circulating Tumor Cells Correlates with Highly Aggressive Disease in Metastatic Breast Cancer<\/p>\n<p align=\"justify\">\n        <strong>Summary:<\/strong> Circulating tumor cells (CTCs) are a well-established non-invasive blood-based biomarker that can help stratify prognosis in patients with metastatic breast cancer (MBC), particularly in aggressive disease subtypes. Early pilot studies had identified a distinct subset of CTCs undergoing mitosis (dividing cells), whose presence appeared to correlate with worse survival outcomes. However, their prognostic significance and potential interaction with different treatment regimens have not been clinically evaluated. In this multi-institutional prospective study, patients with mitotic CTCs were found to have poorer outcomes than those with non-mitotic CTCs or no CTCs, but appeared to have overall survival benefit when treated with targeted therapy. Overall, these findings support mitotic CTCs as a novel potential prognostic biomarker in metastatic breast cancer.<\/p>\n<p align=\"justify\">\n        <strong>Session Category:<\/strong> Clinical Research<br \/><strong>Session Title:<\/strong> Biomarkers Predictive of Therapeutic Benefit 1<br \/><strong>Session: <\/strong>4\/19\/2026 2:00<strong>&#8211;<\/strong>5:00 PM PST<br \/><strong>Location:<\/strong> Poster Section 40<br \/><strong>Poster Board Number:<\/strong> 19<br \/><strong>Poster Number:<\/strong> 1025 <br \/><strong>Title: <\/strong>Monitoring PD-L1 in tumor macrophage fusion cells in blood identifies high PD-L1 checkpoint inhibitor responses in metastatic breast cancer<\/p>\n<p align=\"justify\">\n        <strong>Summary: <\/strong>Tissue biopsy PD-L1 combined positive score (CPS\u226510) has been identified as a positive prognostic marker in metastatic breast cancer. However, a significant percentage of MBC patients with CPS &lt;10 seem to benefit from immune check point inhibitor (ICI) therapy. Circulating tumor-macrophage fusion cells (TMFCs) express PD-L1 and changes in TMFC PD-L1 expression during ICI treatment may explain this outcome. This Phase 2 prospective study found no correlation between tumor PD-L1 CPS and clinical response while demonstrating that patients with PD-L1 positive TMFCs in their blood had significantly improved progression free survival. Monitoring PD-L1 in TMFCs may serve as a real-time biomarker to better indicate ICI response and further studies into the role of TMFC PD-L1 in predicting therapeutic response are ongoing.<\/p>\n<p align=\"justify\">Following the presentation, copies of the posters will be made available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SbQQCNZx1nwvrNE8a_6MTMKt2xOcuRcf-lRt2gafKKl70z-omZYSyGH24AxVSF1qN-3WnnbzQw-tCKc1roWIDMwmjpiI7d6aVh4a9J8HqHZrYv2s0u1XPpLeeQZlh-JKR893mg3_b5KJ32nad005kzG_3t3zbCRcd7a9gEsb0xw=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/scientific-publications\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SbQQCNZx1nwvrNE8a_6MTMKt2xOcuRcf-lRt2gafKKm1k1UYlUMdYYohWSr2vofVEKmuh2RigajIyay1N7ufrunOw6kLLoqecbaMdltgRTo=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting three clinical posters at the 2026 AACR, the contents of such posters, the presentation of positive Phase 3 clinical data demonstrating preserved quality of life in heavily pretreated metastatic breast cancer patients, and the identification of potential prognostic biomarkers based on further analysis of Phase 2 Bria\u2011IMT study data, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company&#8217;s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8nkhGZGno9x2mOvS07hR5G4Me9SoKYc1efY3h-DERfgTCl1Jv-Em2HeaOTt_yZInZ6xpo2yH1IXzH6katgjS5IlGs2WxVvocgIdYskwWWxo=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8nkhGZGno9x2mOvS07hR5CPPazGQGOjUPrqFs-cbu-ozy8W4Se-ITJ0ozzdn1petHV-jkCRMqvothJy0LkA7zA==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ha-OAfk6OF3xBQ7FE8I5jnem_P7yOMN96OetRWNjWy31W0Qp9Ip36bsAgXNcgkzdQQrvwf_L-YQ8I-TCOwFq_bU2cyB8nCzNguUtz3ZwM1E=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cDE2K8Yspr6fnhYylnnGDwi4O0kNANcBUeDTwkDQONXuhsLjObRSp0bvPBLhetKMqewVCmcTgJQ297PYCjwVZyVsC-A0KjKJ_1fbNAMx6AU=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGRjOGM1Y2MtOWJiOS00ZjUxLTlkOWUtNjUyODU4MTc4MzM2LTExMDIyMjktMjAyNi0wNC0yMC1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4\/6 inhibitor treatments shows quality of life (QOL) largely preserved Identification of potential prognostic biomarkers upon further analyses of Phase 2 Bria-IMT\u2122 study data Bria-OTS+\u2122 in Preclinical Cancer Models to be presented on Tuesday April 21 from 2:00- 5:00 PM PST; Poster Number: 6701 PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952771","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4\/6 inhibitor treatments shows quality of life (QOL) largely preserved Identification of potential prognostic biomarkers upon further analyses of Phase 2 Bria-IMT\u2122 study data Bria-OTS+\u2122 in Preclinical Cancer Models to be presented on Tuesday April 21 from 2:00- 5:00 PM PST; Poster Number: 6701 PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April &hellip; Continue reading &quot;BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T11:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting\",\"datePublished\":\"2026-04-20T11:33:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/\"},\"wordCount\":1184,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/\",\"name\":\"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=\",\"datePublished\":\"2026-04-20T11:33:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Market Newsdesk","og_description":"Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4\/6 inhibitor treatments shows quality of life (QOL) largely preserved Identification of potential prognostic biomarkers upon further analyses of Phase 2 Bria-IMT\u2122 study data Bria-OTS+\u2122 in Preclinical Cancer Models to be presented on Tuesday April 21 from 2:00- 5:00 PM PST; Poster Number: 6701 PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April &hellip; Continue reading \"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-20T11:33:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting","datePublished":"2026-04-20T11:33:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/"},"wordCount":1184,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/","name":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=","datePublished":"2026-04-20T11:33:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc4MiM3NTQyOTU3IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952771"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952771\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}